While the shift towards mass production of medicines, in standardised dosages and strengths, helped the industry cater to a wider population base, the need for more specialised dosages or individualised dosing regimens remains prevalent even in recent years. In the modern era, particularly during the ongoing coronavirus health crisis, this need has culminated in a renewed focus on the compounding pharmacies market.
Following three months of treatment, patients with chronic migraine showed a reduction of 2.5 monthly migraine days on average compared to placebo, while patients with episodic migraine saw a reduction of either 1.3 or 1.8 days, depending on the dose taken.
“The key is the nature of prescription demand. Drugs are produced by independent, profit-driven commercial companies (e.g., Merck, AstraZeneca, and GSK)
Considering that compounding is an inherent part of customised medicine, the growing demand for precision therapies in recent years has unearthed lucrative opportunities for compound pharmacies. This in turn has paved the way for several life science companies and compounding pharmacy market players who subsequently amplified their efforts towards the development of personalised medicine.